Frontiers in Oncology (Jun 2024)

Anxiety and depression in patients with non-site-specific cancer symptoms: data from a rapid diagnostic clinic

  • Maria J. Monroy-Iglesias,
  • Beth Russell,
  • Sabine Martin,
  • Louis Fox,
  • Charlotte Moss,
  • Flaminia Bruno,
  • Juliet Millwaters,
  • Lindsay Steward,
  • Colette Murtagh,
  • Carlos Cargaleiro,
  • Darren Bater,
  • Grace Lavelle,
  • Anna Simpson,
  • Jemima Onih,
  • Anna Haire,
  • Clare Reeder,
  • Geraint Jones,
  • Sue Smith,
  • Aida Santaolalla,
  • Mieke Van Hemelrijck,
  • Saoirse Dolly

DOI
https://doi.org/10.3389/fonc.2024.1358888
Journal volume & issue
Vol. 14

Abstract

Read online

BackgroundRapid diagnostic clinics (RDCs) provide a streamlined holistic pathway for patients presenting with non-site specific (NSS) symptoms concerning of malignancy. The current study aimed to: 1) assess the prevalence of anxiety and depression, and 2) identify a combination of patient characteristics and symptoms associated with severe anxiety and depression at Guy’s and St Thomas’ Foundation Trust (GSTT) RDC in Southeast London. Additionally, we compared standard statistical methods with machine learning algorithms for predicting severe anxiety and depression.MethodsPatients seen at GSTT RDC between June 2019 and January 2023 completed the General Anxiety Disorder Questionnaire (GAD-7) and Patient Health Questionnaire (PHQ-8) questionnaires, at baseline. We used logistic regression (LR) and 2 machine learning (ML) algorithms (random forest (RF), support vector machine (SVM)) to predict risk of severe anxiety and severe depression. The models were constructed using a set of sociodemographic and clinical variables.ResultsA total of 1734 patients completed GAD-7 and PHQ-8 questionnaires. Of these, the mean age was 59 years (Standard Deviation: 15.5), and 61.5% (n:1067) were female. Prevalence of severe anxiety (GAD-7 score ≥15) was 13.8% and severe depression (PHQ-8 score≥20) was 9.3%. LR showed that a combination of previous mental health condition (PMH, Adjusted Odds Rario (AOR) 3.28; 95% confidence interval (CI) 2.36–4.56), symptom duration >6 months (AOR 2.20; 95%CI 1.28–3.77), weight loss (AOR 1.88; 95% CI 1.36–2.61), progressive pain (AOR 1.71; 95%CI 1.26–2.32), and fatigue (AOR 1.36; 95%CI 1.01–1.84), was positively associated with severe anxiety. Likewise, a combination PMH condition (AOR 3.95; 95%CI 2.17–5.75), fatigue (AOR 2.11; 95%CI 1.47–3.01), symptom duration >6 months (AOR 1.98; 95%CI 1.06–3.68), weight loss (AOR 1.66; 95%CI 1.13–2.44), and progressive pain (AOR 1.50; 95%CI 1.04–2.16), was positively associated with severe depression. LR and SVM had highest accuracy levels for severe anxiety (LR: 86%, SVM: 85%) and severe depression (SVM: 89%, LR: 86%).ConclusionHigh prevalence of severe anxiety and severe depression was found. PMH, fatigue, weight loss, progressive pain, and symptoms >6 months emerged as combined risk factors for both these psychological comorbidities. RDCs offer an opportunity to alleviate distress in patients with concerning symptoms by expediting diagnostic evaluations.

Keywords